Sheffield Institute for Translational Neuroscience
SITraN is an essential development in the fight against motor neurone disease, other common neurodegenerative disorders, stroke and neuroinflammatory conditions.
MS patients could be offered stem cell transplants as a first-line treatment in new world-first trial
A world-first trial is investigating if stem cell transplantation could be used in patients with aggressive multiple sclerosis (MS) as a first-line treatment.
Promising MND drug helps slow disease progression and benefits patients physically
Scientists believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care, after the results of a Phase 3 clinical trial showed significant physical benefits for patients after 12 months.
Golden Globe Race 2022 - raising money for SITraN
And they’re off! On Sunday 4th September 23 skippers set sail on the prestigious Golden Globe Race. Fundraising for the University of Sheffield’s Institute for Translational Neuroscience, these skippers won’t return for at least 9 months!
Sheffield scientists benefit from £4.25 million to kick start MND research institute
Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded part of a new £4.25 million grant that seeks to discover meaningful MND treatments within years, not decades.